COMPANY OVERVIEW ($CYTO.V)
Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.
Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Stock Information
Shares Outstanding
61,685,221
Warrants
14,993,484
Options
5,816,375
Fully Diluted
82,495,080
Investment Highlights
- Drug-resistant infections caused by overuse of antibiotics has accelerated the demand for bacteriophage-based solutions, (safe, non-toxic and biological)
- Pioneers in bacteriophage R&D and production, with track-record of international competitive awards
- De-risked, replicable technology evidenced by test and trial data
- Only public phage company pursuing solutions for animal health, human health and food safety
- Pipeline of commercialization targets for animal health products:
- European Union: revenue potential pending pilot study results & temporary use authorization
- Canada: revenue potential (LONO and progressing pilot studies)
- Experienced leadership team and board – aligned through investment in company
Cytophage investor call recording
On July 9, 2024, Cytophage held its first Investor Call since going public earlier this year. If you weren’t able to attend, we can provide you with a recording of the call upon request.
Cytophage in the news
NEWS RELEASE
Winnipeg – May 1, 2026 – TheNewswire — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO; FSE: 70G) announces that, as disclosed in the Company’s management’s discussion and analysis for the year ended December 31, 2025 filed on April 30, 2026, Mr. Will Ollerhead has resigned as a director of the Company effective April 29, 2026, to focus on other endeavors.
NEWS RELEASE
Winnipeg – April 14, 2026 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO; FSE: 70G) today announced that the Company’s Chief Operating Officer, Ms. Heather Medwick, has left the Company effective March 31, 2026 as a result of the Company’s comprehensive corporate restructuring.
NEWS RELEASE
Winnipeg – March 6, 2026 Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO; FSE: 70G) today announced that its Board of Directors (the “Board”) has formed a special committee comprised solely of independent and disinterested directors (the “Special Committee”) to evaluate potential strategic alternatives.
Subscribe For Investor Alerts
We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.
Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.
Swine Bacteriophage
We’re helping farmers meet the need and the demand for a healthier food chain.
Funded in part by the Canada and Manitoba governments through the Canadian Agricultural Partnership – Ag Action Manitoba Program. Learn more
Contact Us
Learn more about our bacteriophage solutions.
Cytophage Technologies Ltd. © 2024
